Human albumin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous
Neonatal hyperbilirubinaemia
Child: As human albumin 20% or 25% solution: 1 g/kg before or during exchange transfusion. Treatment recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).

Intravenous
Hypoproteinaemia
Adult: As human albumin 25% solution: 200-300 mL; given at a rate not faster than 100 mL in 30-45 minutes. If slower infusion is desired, 200 mL human albumin 25% solution may be diluted with 300 mL of 10% dextrose solution and given via continuous drip at a rate of 100 mL/hour. Treatment and dosage recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).

Intravenous
Hypovolaemia
Adult: For restoration and maintenance of circulating blood volume: Dosage requirement depends on the weight of the patient, severity of trauma or illness, and on continuing fluid and protein losses. Adjust the concentration of human albumin preparation, dosage, and infusion rate according to individual patient requirements. Low concentration (e.g. 4% or 5% solution) of human albumin is generally preferred for replacement of volume deficit. As human albumin 5% solution: Initially, 12.5-25 g; may repeat after 15-30 minutes if response is inadequate. Human albumin 20-25% solution is recommended if hypovolaemia is long-standing and hypoalbuminaemia exists accompanied by adequate hydration or oedema. Treatment and dosage recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).
Child: As human albumin 5% solution: 0.5-1 g/kg (10-20 mL/kg) over 5-10 minutes. Treatment and dosage recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).

Intravenous
Prevention of central volume depletion following paracentesis due to cirrhotic ascites
Adult: As human albumin 20% or 25% solution: Adjunct treatment: 8 g for every 1,000 mL of ascitic fluid removed. Treatment recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).

Intravenous
Plasma volume expander in severe ovarian hyperstimulation syndrome
Adult: In patients who fail to achieve or maintain urine output and haemodynamic stability with 0.9% NaCl solution: As human albumin 20% or 25% solution: 50-100 g over 4 hours, repeated at 4- to 12-hour intervals as needed. Treatment recommendations may vary among countries and individual product (refer to detailed product or local treatment guidelines).
Hướng dẫn pha thuốc
Human albumin 20% or 25% solution: May be diluted in isotonic solution (e.g. 0.9% NaCl, 5% dextrose).
Tương kỵ
Dilution with sterile water will produce a hypotonic solution that may cause haemolysis and acute renal failure.
Chống chỉ định
Hypersensitivity. Heart failure with normal or increased intravascular volume, severe anaemia. Dilution with sterile water for inj.
Thận trọng
Patient with conditions where hypervolaemia and its consequences or haemodilution may increase the risk of adverse reactions (e.g. hypertension, oesophageal varices, pulmonary oedema, haemorrhagic diathesis, renal and post-renal anuria); severe traumatic brain injury, low cardiac reserve. Postoperative or injured patient. Avoid rapid infusion in patients with history of CV disease. Not recommended as a source of supplemental caloric protein in patients requiring nutritional support. Renal and hepatic impairment. Children. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Severe allergic or anaphylactic reactions, coagulation abnormality, electrolyte imbalance (large volume replacement); cardiac, respiratory, or renal failure; increased intracranial pressure; hypervolaemia.
Cardiac disorders: Tachycardia, bradycardia.
Gastrointestinal disorders: Vomiting, nausea.
General disorders and administration site conditions: Chills, fever, chest tightness.
Nervous system disorders: Headache, tremor, dizziness.
Psychiatric disorders: Confusional state.
Respiratory, thoracic and mediastinal disorders: Stridor, bronchospasm, dyspnoea.
Skin and subcutaneous tissue disorders: Rash erythematosus, angioneurotic oedema, hyperhidrosis, urticaria.
Vascular disorders: Hypertension, hypotension, flushing.
Chỉ số theo dõi
Regularly monitor electrolyte levels, haematocrit or Hb levels, urine output, central venous pressure, pulmonary artery wedge pressure, arterial blood pressure and pulse rate. Closely observe for heart failure and pulmonary oedema during administration.
Quá liều
Symptoms: CV overload (e.g. headache, dyspnoea, jugular vein congestion, increased blood pressure, raised central venous pressure, pulmonary oedema). Management: Discontinue infusion immediately. Carefully monitor haemodynamic parameters of the patient.
Tương tác

Tác dụng
Description: Human albumin, a protein colloid, is a normal component of the plasma and acts like physiological albumin, an essential factor in the regulation of plasma volume and tissue fluid balance. It increases intravascular oncotic pressure, causing movement of fluids from interstitial into intravascular space. It also binds and acts as a carrier of intermediate metabolites (including bilirubin), acidic drugs, fatty acids, hormones, enzymes, trace metals, and dyes.
Pharmacokinetics:
Excretion: Half-life: 15-20 days.
Bảo quản
Store below 30°C. Do not freeze. Protect from light.
Phân loại MIMS
Dung dịch tiêm tĩnh mạch & các loại dung dịch vô trùng khác
Tài liệu tham khảo
Albuminar-25 Solution (CSL Behring LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 10/11/2021.

Albunorm 20%, 200 g/L, Solution for Infusion (Medlink Marketing). MIMS Philippines. http://www.mims.com/philippines. Accessed 24/11/2021.

Albunorm 20%, 200 g/L, Solution for Infusion (Octapharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 23/11/2021.

Albunorm 25%, 250 g/L Solution for Infusion (Pharmaniaga Marketing Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 10/11/2021.

Albunorm 25%, 250 g/L, Solution for Infusion (Medlink Marketing). MIMS Philippines. http://www.mims.com/philippines. Accessed 24/11/2021.

Albunorm 25%, 250 g/L, Solution for Infusion (Octapharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 23/11/2021.

Albunorm 4%, 40 g/L, Solution for Infusion (Octapharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 23/11/2021.

Albunorm 5%, 50 g/L, Solution for Infusion (Octapharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 23/11/2021.

Albutein 20% Injection, Solution (Grifols USA, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 24/11/2021.

Albutein 25% Injection, Solution (Grifols USA, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 24/11/2021.

Anon. Albumin Human. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 23/11/2021.

Anon. Albumin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/11/2021.

Buckingham R (ed). Albumin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/11/2021.

Flexbumin Injection, Solution (Baxalta US Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 10/11/2021.

Human Albumin 200 g/L Baxter (Takeda Pharmaceuticals [Hong Kong] Ltd). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 24/11/2021.

Joint Formulary Committee. Albumin Solution. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/11/2021.

Zenalb 4.5%, 20% Solution (Germax Sdn. Bhd.). MIMS Malaysia. http://www.mims.com/malaysia. Accessed 24/11/2021.

Zenalb 4.5, 45 g/L Solution for Infusion (Bio Products Laboratory Limited). MHRA. https://products.mhra.gov.uk. Accessed 10/11/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Human albumin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Albiomin
  • Albumin 20%-GCC
  • Albuminar
  • AlbuRx
  • Human Albumin (HUMAN BioPlazma)
  • Human Albumin 20% Behring, muối thấp
  • Human Albumin 20% Teva
  • Human Albumin Baxter
  • Plasbumin 20
  • Pulmocis
  • Relab
  • Vabiotech-Albumin
  • Zenalb 20
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in